Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 25, 2024 2:14pm

108 Views

Post# 35845535

RE:RE:RE:RE:“Second mouse gets the cheese “

CGON put up 20 million shares of its common stock up for sale. At the current trading price of $US31.70, CGON's market cap is US$634 million. I don't know how some came up with the market cap figure of $1.5 Billion, unless they are prescient, which I highly doubt given their post posts here.

What CGON's trading shows is that an acquisition value for ONCY of between US $7.5 - 10 Billion is increasingly supported by the uptake of CGON common stock.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments